The Colchicine and atrial fibrillation trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500850-40-01

Enrollment

500

Registered

2022-09-12

Start date

2023-05-26

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation or atrial flutter

Brief summary

Time to first AF admission from start of medication measured in days

Detailed description

Accumulated number of readmissions for symptomatic AF at 12 months, Change in echocardiographic measurements at 12 months, Change of life quality score at 12 months, Change in potentiel side effects at 12 months

Interventions

DRUGPlacebo will be identical in appearance and contain

DRUGthe following ingredients: lactosemonohydrate

DRUGpotato starch

DRUGspiritus gelatinae 5%

DRUGmagnesium stearate

DRUGtalcum.

DRUGCOLCHICINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Time to first AF admission from start of medication measured in days	—

Secondary

Measure	Time frame
Accumulated number of readmissions for symptomatic AF at 12 months, Change in echocardiographic measurements at 12 months, Change of life quality score at 12 months, Change in potentiel side effects at 12 months	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026